Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -239.23 Million USD | -20.97% |
| 2022 | -197.76 Million USD | -46.56% |
| 2021 | -134.94 Million USD | -28.04% |
| 2020 | -105.38 Million USD | -51.23% |
| 2019 | -69.68 Million USD | -125.05% |
| 2018 | -30.96 Million USD | -6.99% |
| 2017 | -28.94 Million USD | -6.4% |
| 2016 | -27.2 Million USD | -157.6% |
| 2015 | -10.55 Million USD | -75.98% |
| 2014 | -6 Million USD | -176.95% |
| 2013 | -2.16 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -68.35 Million USD | 30.71% |
| 2024 Q2 | -79.34 Million USD | -16.07% |
| 2023 Q2 | -67.17 Million USD | -498.77% |
| 2023 Q4 | -98.65 Million USD | -58.61% |
| 2023 Q3 | -62.19 Million USD | 7.4% |
| 2023 Q1 | -11.21 Million USD | 83.2% |
| 2023 FY | -239.23 Million USD | -20.97% |
| 2022 Q4 | -66.76 Million USD | -41.34% |
| 2022 Q2 | -42.83 Million USD | -4.54% |
| 2022 Q1 | -40.97 Million USD | -20.6% |
| 2022 FY | -197.76 Million USD | -46.56% |
| 2022 Q3 | -47.23 Million USD | -10.27% |
| 2021 Q3 | -34.88 Million USD | -8.05% |
| 2021 Q4 | -33.97 Million USD | 2.6% |
| 2021 Q1 | -29.25 Million USD | -0.33% |
| 2021 Q2 | -32.28 Million USD | -10.34% |
| 2021 FY | -134.94 Million USD | -28.04% |
| 2020 FY | -105.38 Million USD | -51.23% |
| 2020 Q3 | -22.92 Million USD | -25.09% |
| 2020 Q2 | -18.32 Million USD | 43.58% |
| 2020 Q1 | -32.48 Million USD | -30.95% |
| 2020 Q4 | -29.16 Million USD | -27.22% |
| 2019 Q1 | -10.64 Million USD | -10.87% |
| 2019 Q4 | -24.8 Million USD | -29.64% |
| 2019 Q3 | -19.13 Million USD | -39.04% |
| 2019 FY | -69.68 Million USD | -125.05% |
| 2019 Q2 | -13.76 Million USD | -29.34% |
| 2018 FY | -30.96 Million USD | -6.99% |
| 2018 Q4 | -9.59 Million USD | -15.88% |
| 2018 Q3 | -8.28 Million USD | -0.01% |
| 2018 Q2 | -8.28 Million USD | -72.32% |
| 2018 Q1 | -4.8 Million USD | 35.33% |
| 2017 FY | -28.94 Million USD | -6.4% |
| 2017 Q1 | -7.99 Million USD | -9.09% |
| 2017 Q3 | -6.43 Million USD | 9.19% |
| 2017 Q2 | -7.08 Million USD | 11.39% |
| 2017 Q4 | -7.43 Million USD | -15.5% |
| 2016 FY | -27.2 Million USD | -157.6% |
| 2016 Q4 | -7.32 Million USD | -1.87% |
| 2016 Q3 | -7.19 Million USD | -5.61% |
| 2016 Q2 | -6.81 Million USD | -16.13% |
| 2016 Q1 | -5.86 Million USD | -242.25% |
| 2015 FY | -10.55 Million USD | -75.98% |
| 2015 Q4 | -1.71 Million USD | 62.55% |
| 2015 Q3 | -4.57 Million USD | -114.9% |
| 2015 Q2 | -2.12 Million USD | 0.5% |
| 2015 Q1 | -2.14 Million USD | -43.7% |
| 2014 FY | -6 Million USD | -176.95% |
| 2014 Q1 | -2.12 Million USD | 0.0% |
| 2014 Q4 | -1.48 Million USD | -488.37% |
| 2014 Q3 | -253.11 Thousand USD | 88.11% |
| 2014 Q2 | -2.12 Million USD | 0.0% |
| 2013 FY | -2.16 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -56.141% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3644.53% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 18279.179% |
| Perrigo Company plc | -12.7 Million USD | -1783.764% |
| Illumina, Inc. | -1.16 Billion USD | 79.394% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 103.991% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 46.122% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.23% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 117.617% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -116.389% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 106.051% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -500.196% |
| Waters Corporation | 642.23 Million USD | 137.251% |
| Biogen Inc. | 1.16 Billion USD | 120.604% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 7.211% |
| Evolus, Inc. | -61.68 Million USD | -287.838% |
| Adicet Bio, Inc. | -142.65 Million USD | -67.7% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -101.866% |
| bluebird bio, Inc. | -211.91 Million USD | -12.894% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -14.332% |
| FibroGen, Inc. | -284.23 Million USD | 15.83% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 119.293% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -436.368% |
| Homology Medicines, Inc. | -53.74 Million USD | -345.152% |
| Geron Corporation | -184.12 Million USD | -29.931% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 45.658% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -57.825% |
| Myriad Genetics, Inc. | -112 Million USD | -113.605% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -178.524% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 50.282% |
| Zoetis Inc. | 2.34 Billion USD | 110.206% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -341.496% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 130.33% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 242.705% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 106.61% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -466.928% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 34.685% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 13.359% |
| Verastem, Inc. | -87.36 Million USD | -173.831% |
| Nektar Therapeutics | -276.05 Million USD | 13.337% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -170.383% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 55.364% |
| OPKO Health, Inc. | -188.86 Million USD | -26.673% |
| Exelixis, Inc. | 207.76 Million USD | 215.148% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 195.81% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 325.399% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -403.606% |
| uniQure N.V. | -308.47 Million USD | 22.446% |
| Imunon, Inc. | -19.51 Million USD | -1125.92% |
| Blueprint Medicines Corporation | -506.98 Million USD | 52.812% |
| Insmed Incorporated | -749.56 Million USD | 68.083% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 184.958% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 32.052% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1987.926% |
| Incyte Corporation | 597.59 Million USD | 140.033% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 68.542% |